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The cellular immune response to respiratory syncytial virus (RSV) is important in both protection and
immunopathogenesis. In contrast to HLA class I, HLA class II-restricted RSV-specific T-cell epitopes have not
been identified. Here, we describe the generation and characterization of two human RSV-specific CD4-T-cell
clones (TCCs) associated with type 0-like cytokine profiles. TCC 1 was specific for the matrix protein and
restricted over HLA-DPB1*1601, while TCC 2 was specific for the attachment protein G and restricted over
either HLA-DPB1*0401 or -0402. Interestingly, the latter epitope is conserved in both RSV type A and B
viruses. Given the high allele frequencies of HLA-DPB1*0401 and -0402 worldwide, this epitope could be widely
recognized and boosted by recurrent RSV infections. Indeed, peptide stimulation of peripheral blood mono-
nuclear cells from healthy adults resulted in the detection of specific responses in 8 of 13 donors. Additional
G-specific TCCs were generated from three of these cultures, which recognized the identical (n  2) or almost
identical (n  1) HLA-DP4-restricted epitope as TCC 2. No significant differences were found between the
capacities of cell lines obtained from infants with severe (n  41) or mild (n  46) RSV lower respiratory tract
infections to function as antigen-presenting cells to the G-specific TCCs, suggesting that the severity of RSV
disease is not linked to the allelic frequency of HLA-DP4. In conclusion, we have identified an RSV G-specific
human T helper cell epitope restricted by the widely expressed HLA class II alleles DPB1*0401 and -0402. Its
putative role in protection and/or immunopathogenesis remains to be determined.
Respiratory syncytial virus (RSV), a member of the genus
Pneumovirus of the family Paramyxoviridae, is a major cause of
severe lower respiratory tract disease in infants, immunocom-
promised individuals, and the elderly (7, 29). RSV infections
cause yearly epidemics in the winter season of moderate cli-
mate zones and are most often associated with relatively mild
upper respiratory tract infections (29). In general, specific im-
munity is insufficient for protection, and RSV infections con-
tinue to occur throughout life.
At present, no licensed RSV vaccine is available. During
vaccine trials in the 1960s, vaccination with a formalin-inacti-
vated whole-virus preparation (FI-RSV) was found to predis-
pose for enhanced clinical disease following natural infection
with RSV (17). Although the exact mechanism of this appar-
ently immunopathological phenomenon remains unclear, stud-
ies of both rodent and nonhuman primate models have sug-
gested that a skewed RSV-specific T helper type 2 (Th2)
response was a key factor in this process (11, 23). Several
studies have suggested that primary infections in young infants
resulting in severe RSV bronchiolitis are also associated with
Th2 responses (24, 28). However, in two other cohort studies
of infants with either severe RSV bronchiolitis or relatively
mild RSV upper respiratory tract infection, this observation
was not confirmed (6, 12).
Few studies have described the RSV-specific T-cell response
at the epitope level. In rodents, four T-cell epitopes have been
described, of which three were MHC class I and one was class
II-restricted. The MHC class I-restricted epitopes were located
in the RSV F protein (10, 16) and the RSV M2 protein (19),
whereas the MHC class II-restricted epitope was located in the
RSV G protein (33). In humans, class I-restricted epitopes
have been identified in the RSV F (5, 27) and NP (14, 34)
proteins. However, no human class II-restricted T-cell epitopes
have been described. Recently, van Bleek et al. (32) described
the human CD4 response to the RSV F protein. Using a set of
overlapping peptides, they were able to demonstrate ex vivo
F-specific CD4 memory T-cell responses. Similar RSV F-spe-
cific CD4 responses were also described earlier by Levely et al.
(20).
In the present study, we describe two RSV-specific CD4-
T-cell clones (TCCs) generated from clinical materials col-
lected from infants during the acute or convalescent phase of
a laboratory-confirmed RSV infection. Gamma interferon
(IFN-) enzyme-linked immunospot (ELISPOT) assays were
used to determine the protein specificity, minimal epitope, and
HLA restriction element.
MATERIALS AND METHODS
Antigen-presenting cell (APC) lines. Autologous B-lymphoblastic cell lines
(BLCL) were established by transformation of peripheral blood mononuclear
cells (PBMC) with Epstein-Barr virus as described previously (31). For the
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generation of target and/or stimulator cells, BLCL were infected with
RSV-A2 (ATCC VR1322) at a multiplicity of infection of 100, resulting in
persistently infected BLCL (BLCL-RSV) as previously described (3). The per-
centage of RSV-positive cells was checked by FACScan with fluorescein isothio-
cyanate-labeled RSV-specific monoclonal antibodies (MAbs) (Imagen; DAKO,
Glostrup, Denmark). All BLCL were maintained in RPMI 1640 medium (Bio-
Whittaker, Verviers, Belgium) containing penicillin (100 U/ml; BioWhittaker),
streptomycin (100 g/ml; BioWhittaker), L-glutamine (2 mM; BioWhittaker),
-mercaptoethanol (105 M; Merck, Darmstadt, Germany) (referred to below as
culture medium) supplemented with 10% heat-inactivated (30 min; 56°C) fetal
bovine serum (Greiner, Frickenhausen, Germany). BLCL used for restriction
element analysis were obtained from the European Collection of Cell Cultures
(cells lines represented by “I” followed by the International Histocompatibility
Workshop number) or were in-house generated (represented by “E” followed by
a unique number). For autologous and in-house-generated BLCL, molecular
typing of the HLA-DRB1*, DQB1*, and DPB1* loci was performed using a
commercial typing system (GenoVision, Vienna, Austria).
Generation of RSV-specific T-cell clones. TCC 1 was generated from nasal-
brush cells collected from an infant (age, 20 months) during the acute phase of
a laboratory-confirmed RSV-mediated upper respiratory tract infection. The
nasal-brush T cells were stimulated in vitro with autologous -irradiated (3,000
rad) BLCL-RSV, and TCCs were generated by limiting dilution as described
before (35). In short, T cells were seeded in 60-well Terasaki plates (Greiner
Bio-One, Frickenhausen, Germany) at concentrations of 3, 1, and 0.3 per well
and stimulated with allogeneic feeder cells and recombinant human interleukin-2
(rhIL-2; Red Swan, Utrecht, The Netherlands). After 2 weeks of expansion,
positive cultures were restimulated specifically using -irradiated autologous
BLCL-RSV, expanded with rhIL-2, and tested for RSV specificity in an IFN-
ELISPOT assay (see below) after stimulation with BLCL or BLCL-RSV. RSV-
specific TCCs were phenotyped by fluorescence using MAbs against CD3, CD4,
and CD8 (DAKO).
TCC 2 was generated from PBMC collected from another infant (age, 2
months) during the convalescent phase of an RSV-mediated lower respiratory
tract infection. PBMC were stimulated in vitro with -irradiated autologous
BLCL-RSV, and TCCs were generated by limiting dilution as described above.
TCCs P1, P2, and P3 were generated from PBMC collected from healthy adult
donors. PBMC were stimulated in vitro with peptide G158-189 (0.01 M), and
TCCs were generated by limiting dilution as described above.
FIG. 1. RSV specificities of TCC 1 (A) and TCC 2 (D) were determined in an IFN- ELISPOT assay, using autologous BLCL either uninfected
(BLCL) or infected with RSV (BLCL-RSV) or pulsed with antigen (BLCLBPL-Vero and BLCLBPL-RSV). The protein specificities of TCC
1 (B) and TCC 2 (E) were determined using autologous BLCL infected with different rVV constructs. The minimal epitopes recognized by TCC
1 (C) and TCC 2 (F) were determined by using autologous BLCL pulsed overnight with 0.1 (C) or 0.01 (F) M peptide. The results are shown
as SFC per well.
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T cells and T-cell lines were maintained in culture medium supplemented with
pooled 10% heat-inactivated human serum (referred to below as R10H) and
rhIL-2.
ELISPOT assay. The reactivities of TCCs with APCs were determined in an
IFN- ELISPOT assay as described previously (12). In short, TCCs were seeded
in concentrations ranging from 4,000 to 10,000 per well in a 96-well V-bottom
plate (Greiner Bio-One), and APCs were added in an effector-to-target ratio of
1:5 and incubated for 1 h at 37°C. The cells were transferred to nylon bottom
plates (Nalge Nunc, Rochester, N.Y.) precoated with a MAb against IFN-
(1-D1K; Mabtech AB, Stockholm, Sweden), incubated for 4 h at 37°C, and
subsequently washed with phosphate-buffered saline containing 0.05% Tween 20
(Merck). The spots were visualized by incubation with a secondary biotinylated
MAb against IFN- (7-B6-1; Mabtech AB), streptavidin alkaline phosphatase
(Mabtech AB), and nitroblue tetrazolium–5-bromo-4-chloro-3-indolylphosphate
(Kirkegaard & Perry Laboratories, Gaithersburg, Md.). Finally, the color reac-
tion was stopped by washing the plates with distilled water, and the spots were
counted with a stereomicroscope at 25-fold magnification. IFN- ELISPOT re-
sults are shown in figures and tables as IFN- spot-forming cells (SFC) per well.
RSV protein specificity. Recombinant vaccinia virus (rVV) constructs medi-
ating the expression of the individual proteins of RSV (rVV-F, -G, -M, -P, -N,
-1A, -1B, -1C, -L, and -22K) and a wild-type VV were used to infect autologous
BLCL at a multiplicity of infection of 10. rVV-infected BLCL were used as APCs
in IFN- ELISPOT assays to determine protein specificities.
Peptide-specific T-cell responses. For evaluation of the responses to different
peptides, BLCL were pulsed overnight with peptides at different concentrations
(1 to 0.001 M) and subsequently used as APCs in IFN- ELISPOT assays.
For TCC 1, 15-mer peptides (n  49) with 5-amino-acid overlaps spanning the
M protein (GenBank accession no. P03419) were tested (last peptide, 16 amino
acids). For fine T-cell epitope mapping, peptides were constructed with one or
more deletions on either the N-terminal or C-terminal side. Peptides with free N
and C termini were synthesized as described before (13), dissolved in dimethyl
sulfoxide at a concentration of 10 mg/ml, and diluted to 100 M in RPMI 1640
(BioWhittaker).
For TCC 2, a 101-mer peptide spanning the conserved region of the RSV G
protein (G2Na; amino acids 130 to 230; kindly provided by U. F. Power, Centre
d’Immunologie Pierre-Fabre, Saint-Julien-en-Genevois, France) and smaller
peptides spanning different regions of G2Na (G170-187, G187-223, G187-198,
G174-189, and G158-189) were tested. For fine epitope mapping, overlapping 15-
mers with 14-amino-acid overlaps or deletion mutants were used.
The protein preparations used to pulse BLCL overnight at a concentration of
1 g/ml were -propiolactone (Sigma Aldrich, St. Louis, Mo.) inactivated RSV
(BPL-RSV cultured in Vero cells) and Vero cell antigen (BPL-Vero), as de-
scribed by De Swart et al. (11).
RSV-specific T-cell responses in PBMC or CBMC. PBMC collected from
healthy adults or cord blood mononuclear cells (CBMC) were stimulated with
peptide G158-189 (0.1 or 0.01 M) in R10H and expanded in the presence of
rhIL-2. After 2.5 weeks of culture, the outgrowth of specific cells was analyzed in
a CD69 expression assay as described before (30). In short, residual CD69
molecules were enzymatically removed (0.1% chymotrypsin type II [Sigma Al-
drich] in PBS; 10 min; 37°C), and subsequently the cells were stimulated with
autologous BLCL pulsed with peptide G158-189 (positive) or G174-189 (negative).
After 6 h, the cells were washed; incubated with CD3-FITC (DAKO),
CD69-PE (BD Pharmingen), CD8-PerCP (BD Pharmingen), and CD4-APC
(BD Pharmingen); and analyzed in a FACSCalibur (Becton-Dickinson, Erem-
bodegem, Belgium).
Cytokine enzyme-linked immunosorbent assays. To determine cytokine pro-
files, TCCs (105 per well) were stimulated in vitro with autologous BLCL either
uninfected or infected with RSV or were pulsed overnight with peptides (0.1
M) M245-256 and M241-251 (TCC 1 positive and negative peptides, respectively)
or G161-175 and G167-181 (TCC P3 positive and negative peptides, respectively), at
an effector-to-target ratio of 2:1. After 5 days, the culture supernatants were
harvested, and cytokine levels were determined according to the manufacturer’s
instructions for IFN-, IL-2, IL-4, and IL-5 (Biosource, Fleurus, Belgium) and
IL-13 (U-Cytech, Utrecht, The Netherlands).
RESULTS
Generation and characterization of human RSV-specific
T-cell clones. TCC 1 was cloned from nasal-brush cells col-
lected from an infant during the acute phase of a laboratory-
confirmed RSV upper respiratory tract infection. It was RSV
specific (Fig. 1A), of the CD3 CD4 phenotype, and it rec-
ognized the RSV M protein (Fig. 1B). Of the overlapping pep-
tides tested, peptide N241 WKHTATRFAIKPMED256 was rec-
ognized, and the minimal epitope was R248FAIKPME255 with
an additional amino acid on either side (Fig. 1C).
TCC 2 was cloned from PBMC collected from an infant
during the convalescent phase of an RSV lower respiratory
tract infection. It was RSV specific (Fig. 1D), of the CD3
CD4 phenotype, and it recognized the RSV G protein (Fig.
1E). The clone was also found to recognize BLCL pulsed with
G2Na or with G158-189 (data not shown). The minimal epitope
was F163HFEVFNFV171 (Fig. 1F).
Analysis of published sequences suggested that the M
epitope is conserved in RSV A but not in RSV B, whereas
the G epitope is conserved in both subgroups (results not
shown). This was confirmed in an IFN- ELISPOT assay
using autologous BLCL pulsed with RSV A (Long strain;
ATCC VR26) or RSV B (B1 strain; ATCC 1400) antigens as
APCs. Whereas the G-specific TCC P2 was able to recognize
both RSV A- and B-pulsed APCs, the M-specific TCC 1 was
capable of recognizing only RSV A-pulsed APCs (data not
shown).
Determination of HLA restriction elements of TCCs 1
and 2. The class II genotype of the donor from whom TCC
1 originated was HLA-DRB1*0301,0701;DQB1*0201,0202;
DPB1*1101,1601; that of the donor of TCC 2 was HLA-
DRB1*0102,0701;DQB1*0303,0501;DPB1*0201,0401. By
TABLE 1. Determination of HLA restriction elements of TCC 1
BLCL
Restriction elementsc
Aut.a E-0002 I-9019 I-9023 I-9050 I-9095 I-9041 I-9063
DRB1* 0301 0102 0301 0301 1104 1302
DRB1* 0701 0701 0701 0701
DQB1* 0201 0303 0201 0201 0201 0301 0604
DQB1* 0202 0501 0202 030302
DPB1* 1101 0201 0402 0101 020102 0401 1101
DPB1* 1601 0401 1301 0402 1601
IFN- SFCb 168 3 2 0 2 1 2 188
a Aut., autologous BLCL.
b IFN- SFC per well were obtained by using BLCL pulsed with M241–256.
c HLA class II phenotypes that BLCL have in common with the autologous
BLCL are in boldface.
TABLE 2. Determination of HLA restriction elements of TCC 2
BLCL
Restriction elementc
Aut.a E-0004 E-0001 E-7366 I-9003 I-9105 I-9026 E-0003 I-9013
DRB1* 0102 0102 0301 1501 0101 11041 0402 1301 1501
DRB1* 0701 0302 0701 0701 1501
DQB1* 0303 0402 0201 0202 0603 0302 0602 0602
DQB1* 0501 0501 0202 0602 0501 0603
DPB1* 0201 0101 1101 0301 1301 0201 0402 0402
DPB1* 0401 0301 1601 1001 0401 0401
IFN-
SFCb
126 1 0 3 1 3 145 130 122
a Aut., autologous BLCL.
b IFN- SFC per well were obtained by using BLCL pulsed with G158-189.
c HLA class II phenotypes that BLCL have in common with the autologous
BLCL are in boldface.
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testing reactivity with peptide-pulsed BLCL matched or mis-
matched for HLA-DR or -DQ, we were unable to determine
the restriction pattern for either of these TCCs: for TCC 1, no
responses were found, while for TCC 2, the majority of the
APCs resulted in positive responses. When the HLA-DP al-
leles were included, it was found that TCC 1 was restricted by
HLA-DPB1*1601 (Table 1), while TCC 2 recognized pep-
tide in the context of either HLA-DPB1*0401 or -0402 (Ta-
ble 2).
Peptide G158-189 responses in the human population. Since
HLA-DPB1*0401 and -0402 are the most frequent HLA class
II alleles in the human population (8), we investigated the
response to peptide G158-189 in PBMC obtained from healthy
adult donors and in CBMC. No specific T cells were found in
the CBMC cultures, while G158-189-specific T cells were de-
tected in 8 of 13 PBMC cultures (Fig. 2).
In order to confirm that the G158-189-expanded cells were
indeed RSV-specific T cells, TCCs were generated from
three of these cultures (P1, P2, and P3), and the minimal
epitopes of these TCCs were determined. As shown in Fig.
3, TCC P1 and TCC P2 recognized the same minimal epi-
tope as TCC 2, while TCC P3 recognized a 10-mer peptide
shifted 1 amino acid in the C-terminal direction, H162FEVF
NFVPC173.
The class II genotype of donor P1 was HLA-DRB1*1301,
1501;DQB1*0602,0603;DPB1*0401,0402, that of donor P2 was
HLA-DRB1*0401,1201;DQB1*0301;DPB1*0301,0402, and
that of donor P3 was HLA-DRB1*1201,1501;DQB1*0301,
0601;DPB1*0201,0401. Similarly to TCC 2, both TCCs P1 and
P2 recognized peptide in the context of HLA-DPB1*0401 or
-0402 (Tables 3 and 4). Interestingly, TCC P3 was also able to
recognize peptide in the context of HLA-DPB1*0201 and
-02012 (Table 5).
FIG. 2. Detection of G158-189-specific T cells in CBMC (C1 to C9)
or PBMC (P1 to P13) stimulated for 2.5 weeks with 0.01 M peptide
G158-189. The percentage of CD69
 cells in the CD3 CD4 fraction of
the expanded bulk cultures was determined after 6 h of stimulation
with autologous BLCL pulsed with G174-189 (negative; open bars) or
G158-189 (positive; black bars). Responses were considered positive
when the ratio of the percentages of CD69 cells after stimulation with
the positive and negative peptides was 2.
FIG. 3. Determination of the minimal epitopes of TCC-P1, -P2,
and -P3 in an IFN- ELISPOT assay using autologous BLCL pulsed
with 0.01 M G158-189 as APCs. The results are shown as SFC per well.
TABLE 3. Determination of HLA restriction elements of TCC P1
BLCL
Restriction elementc
Aut.a I-9060 E-7366 I-9013 I-9105 I-9016 I-9002 I-9026
DRB1* 1301 1301 0701 11041 1602 0102 0402
DRB1* 1501 1501 1501
DQB1* 0602 0602 0602 0301 0501 0302
DQB1* 0603 0603 0202 0603
DPB1* 0401 0301 0201 0401 0401
DPB1* 0402 1001 0402 0402
IFN- SFCb 200 0 1 140 10 126 190 180
a Aut., autologous BLCL.
b IFN- SFC per well were obtained by using BLCL pulsed with G158-189.
c HLA class II phenotypes that BLCL have in common with the autologous
BLCL are in boldface.
TABLE 4. Determination of HLA restriction elements of TCC P2
BLCL
Restriction elementc
Aut.a I-9032 I-9038 I-9016 I-9043 E-1519 I-9013 I-9002
DRB1* 0401 0401 1602 1101 0801 0102
DRB1* 1201 1201 1401 1501
DQB1* 0301 0302 0301 0301 0301 0402 0602 0501
DQB1* 0503
DPB1* 0301 02012 02012 1001 0301 0401
DPB1* 0402 0402 0501 0402
IFN- SFCb 180 3 2 165 0 6 175 185
a Aut., autologous BLCL.
b IFN- SFC per well were obtained by using BLCL pulsed with G158-189.
c HLA class II phenotypes that BLCL have in common with the autologous
BLCL are in boldface.
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All TCCs produce both type 1 and 2 cytokines. TCCs 1 (two
subclones), P2, and P3 were tested for the ability to produce
cytokines after stimulation with different antigens. All of the
TCCs showed specific cytokine production after stimulation
with RSV-infected or peptide-pulsed autologous BLCL, with
IFN- and IL-13 predominating. Interestingly, while TCC 1
(both subclones) produced higher levels of IL-5 than IL-4 upon
stimulation, TCCs P2 and P3 produced more IL-4 than IL-5
(Fig. 4 and data not shown).
HLA-DP4 phenotype in infants with RSV infections of dif-
ferent clinical severities. To determine if the T-cell response to
the HLA-DP4-restricted G epitope plays a role in the patho-
genesis of severe RSV disease, the allelic frequency of HLA-
DP4 or the precursor frequency of the G-specific T cells could
be compared among infants with RSV disease of different
severities. As an alternative to the determination of HLA-DP4
allelic frequencies, specimens from a previous cohort study (6)
allowed us to test the functional capacities of BLCL obtained
from infants with severe or mild RSV lower respiratory tract
infections to function as APCs to the G-specific TCCs. Positive
responses of the TCCs were found after stimulation by 35 of 41
(85%) and 50 of 64 (78%) peptide-pulsed BLCL, respectively
(no significant difference; P  0.1; Fisher’s exact test, two sided).
FIG. 4. Cytokine levels in culture supernatants of TCC 1 (A) and TCC P3 (B) 5 days after stimulation with medium, autologous (aut.) BLCL,
autologous BLCL-RSV, autologous BLCL pulsed with negative (neg.) peptide (M241-251 for TCC 1 and G167-181 for TCC P3), or autologous BLCL
pulsed with positive (pos.) peptide (M245-256 for TCC 1 and G161-175 for TCC P3). The detection limits were 10 pg/ml for IFN- (solid bars), IL-2
(open bars), IL-4 (shaded bars), and IL-5 (hatched bars) and 100 pg/ml for IL-13 (cross-hatched bars).
TABLE 5. Determination of HLA restriction elements of TCC P3
BLCL
Restriction elementc
Aut.a I-9038 E-7366 I-9016 I-9043 E-0005 I-9105 I-9050 I-9002 I-9013
DRB1* 1201 1201 0701 1602 1101 1502 11041 0701 0102
DRB1* 1501 1501 1501
DQB1* 0301 0301 0602 0301 0301 0202 0501 0602
DQB1* 0601 0202 0601 0603
DPB1* 0201 02012 0301 0402 1001 0901 0201 02012 0402
DPB1* 0401 1001 0401
IFN-
SFCb
125 80 1 104 2 1 130 80 124 112
a Aut., autologous BLCL.
b IFN- SFC per well were obtained by using BLCL pulsed with G158-189.
c HLA class II phenotypes that BLCL have in common with the autologous
BLCL are in boldface.
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DISCUSSION
We have identified two HLA-DP-restricted T helper cell
epitopes in the RSV M and G proteins, conserved in subgroup
A and in both subgroups A and B, respectively. The M epitope
was recognized by a TCC restricted by HLA-DPB1*1601,
while the G epitope was recognized in the context of either
HLA-DPB1*0401 or -0402. The ubiquitous distribution of the
last alleles and the results of our peptide PBMC bulk stimu-
lations suggest that responses to the G epitope are generated
in a large part of the human population.
The majority of studies of human T helper cell responses
have focused on HLA-DR- and -DQ-restricted T cells, to a
large extent because HLA-DP appeared less important in con-
tributing to the risk of graft-versus-host disease (21). However,
several HLA-DP-restricted T-cell epitopes have now been de-
scribed (2), including viral epitopes (9, 18). To our knowledge,
the RSV M-specific TCC described here is the first HLA-
DPB1*1601-restricted epitope identified. Recently, a number
of TCCs have been described as recognizing their epitopes in
the context of HLA-DPB1*0401 and/or -0402, which both be-
long to the serologically defined HLA-DPw4 antigenic group
(4). HLA-DPw4 is the most prevalent HLA class II antigen,
with an allelic frequency of 78% in the Caucasian population
(1). The RSV G epitope identified in the present paper is con-
sistent with the suggested motif for HLA-DP4-restricted epi-
topes as previously described (8).
HLA-DPB1*0401 and -0402 differ by only 3 amino acids,
and TCCs raised in subjects with HLA-DPB1*0401 were in
some cases also able to recognize their antigens in the context
of HLA-DPB1*0402 (4). We have found the same in the donor
of TCC 2 and in donor P3, but have also raised a TCC in a
donor who was HLA-DPB1*0402 positive (donor P3) that
could recognize its epitope in the context of HLA-DPB1*0401.
This TCC, which recognized an epitope that was shifted 1
amino acid in the C-terminal direction compared to TCCs 2,
P1, and P2, could also recognize its epitope in the context of
HLA-DPB1*0201 and -02012. Interestingly, HLA-DPB1*0201
and HLA-DPB1*0402 differ by only 1 amino acid in the P4
pocket of the peptide-binding groove, and HLA-DP2 and
-DP4 were previously suggested to form a supertype of class II
molecules on the basis of homology in the peptide-binding
pockets P1 and P6 (8).
The functional studies using BLCL from infants with mild or
severe RSV-mediated lower respiratory tract disease as APCs
to the G-specific TCCs suggested that the severity of RSV
disease is not linked to the allelic frequency of HLA-DP4.
However, frequency studies of epitope-specific T cells in in-
fants with different disease severities will have to be performed
to determine whether they play a role in RSV pathogenesis.
The fact that the conserved HLA-DP4-restricted epitope was
found in the G protein brings another dimension to this ques-
tion, since G-specific responses have often been suggested to
be involved in natural or vaccine-mediated enhanced disease
(15, 22). However, in our study, similar Th0-like cytokine pro-
duction profiles were found for both the M- and G-specific
TCCs.
Castelli et al. suggested that specific HLA-DP4-restricted
epitopes could be used as peptide vaccines, because of the high
frequency of HLA-DP4 worldwide (8). However, vaccination
with nonreplicating RSV vaccines that induce only HLA class
II-restricted T-cell responses has been associated with immu-
nopathology in humans (17), nonhuman primates (11, 25), and
rodents (23, 26).
In conclusion, we have identified the first HLA-DPB1*1601-
restricted T-cell epitope and a conserved HLA-DP4-restricted
T-cell epitope in the RSV M and G proteins, respectively.
Whether immune responses to the latter epitope are involved
in RSV-mediated immunopathogenesis remains to be deter-
mined.
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